REDWOOD CITY, Calif.,
Sept. 14, 2020 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that the U.S. military's
access to DSUVIA has been expanded with the addition of DSUVIA to
the Department of Defense's Joint Deployment Formulary (JDF).
The JDF is a core list of pharmaceutical products that are
designated for deploying military units across all service
branches.
"DSUVIA's addition to the Joint Deployment Formulary continues
to validate its importance as a key option in the treatment of
acute pain and represents yet another significant milestone for
AcelRx," said Vince Angotti, Chief
Executive Officer at AcelRx Pharmaceuticals. "DSUVIA's advancement
within the military coupled with recently published data showing
how DSUVIA enhances recovery times in the post-operative setting
supports the increasing momentum for DSUVIA use and allows more
healthcare practitioners to experience DSUVIA's unique
pharmacokinetic characteristics," stated Mr. Angotti.
About DSUVIA (sufentanil sublingual tablet), 30
mcg
DSUVIA®, known as DZUVEO® in Europe, approved by the FDA in November 2018, is indicated for use in adults in
certified medically supervised healthcare settings, such as
hospitals, surgical centers, and emergency departments, for the
management of acute pain severe enough to require an opioid
analgesic, and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile
when delivered sublingually avoids the high peak plasma levels and
short duration of action observed with IV administration. The
European Commission approved DZUVEO for marketing in Europe in June
2018 and the Company is currently in discussions with
potential European marketing partners.
This release is intended for investors only. For more
information, including important safety information and black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S.,
DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as
DZUVEO® in Europe, indicated
for the management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and one product candidate,
Zalviso® (sufentanil sublingual tablet system, SST system, 15
mcg), an investigational product in the U.S., is being developed as
an innovatively designed patient-controlled analgesia (PCA) system
for reduction of moderate-to-severe acute pain in medically
supervised settings. DZUVEO and Zalviso are both approved products
in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
Forward-Looking Statements
This press
release contains forward-looking statements, including, but not
limited to, statements related to the expected use of DSUVIA by
more healthcare practitioners. These and any other
forward-looking statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by the use
of forward-looking terminology such as "believes," "expects,"
"anticipates," "may," "will," "should," "seeks," "approximately,"
"intends," "plans," "estimates," or the negative of these words or
other comparable terminology. The discussion of strategy, plans or
intentions may also include forward-looking statements. These
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from those
projected, anticipated or implied by such statements. In
addition, such risks and uncertainties may include, but are
not limited to, those described in the Company's annual, quarterly
and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as
filed or furnished with the Securities and Exchange Commission
(SEC). You are cautioned not to place undue reliance on any such
forward-looking statements, which speak only as of the date such
statements were first made. The Company's SEC reports are available
at www.acelrx.com under the "Investors" tab. Except to the extent
required by law, the Company undertakes no obligation to publicly
release the result of any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of unanticipated
events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-announces-dsuvia-added-to-the-us-department-of-defenses-joint-deployment-formulary-301129926.html
SOURCE AcelRx Pharmaceuticals, Inc.